AKT1 and melanoma: Therefore, studies focusing on trametinib and dabrafenib-resistant melanoma (TDR) cell lines were conducted, and it observed that BMS-754807 hindered cellular growth and led to a decrease in intracellular p-Akt levels within TDR cells [33].